Associate Director - CMC (Chemistry, Manufacturing, and Controls)
- Employer
- Mammoth Biosciences
- Location
- Brisbane, CA
- Start date
- Jul 10, 2024
View more categoriesView less categories
- Discipline
- Manufacturing & Production, Science/R&D, Chemistry, CMC
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Biotech Bay
Job Details
Mammoth Biosciences is hiring an Associate Director, CMC to be a key player in our product development teams, providing support across all developmental and clinical programs. The successful candidate will be involved in managing a network of CDMOs for Drug substance and Drug Product manufacturing for Mammoth’s pipeline.
KEY RESPONSIBILITIES
- Provide broad CMC support for internal programs from GLP tox through IND clinical programs
- Ensure timely Drug Substance/Drug Product supply for non-clinical and clinical studies
- Lead management of CMOs for process development and manufacturing of Drug Substances and Drug Products for toxicology and cGMP supplies
- Develop and execute CMC strategies for early phase as well as late phase Drug Substance/Drug Product clinical supplies
- Responsible for phase appropriate development and practical implementation of processes and controls for regulatory materials, intermediates, and drug substances and drug products
- Coordinate with internal and external analytical/quality control, quality assurance, and regulatory team members to resolve technical issues or deviations during cGMP production
- Create and manage contracts, requests for pricing, supply agreements, etc., related to drug substance and drug product manufacturing
- Ensure activities are executed in alignment with established Quality Agreements. Author, review, and adjudicate relevant CMC sections for US and ex-US regulatory filings as needed
- Work closely with cross functional teams to ensure seamless transitions between drug substance and drug product programs and suppliers
- Develop and maintain collaborative relationships with internal stakeholders (e.g., Discovery, Non-Clinical, CMC, Clinical Operations, Regulatory, Quality, Finance, etc.) to deliver on internal goals and objectives
REQUIRED QUALIFICATIONS
- Bachelor’s Degree in technical field or equivalent
- Minimum of 10 years' experience in Biotech in large and small molecules
- Strong process understanding in one or some of: biologics, oligonucleotide, cell therapy, viral vectors, gene therapy or LNP
- Experience in management of external CDMOs for DS/DP production
- Strong understand of phase appropriate analytical development and manufacturing strategies for large and small molecules
- Experience with US and EU CMC regulatory expectations, technical transfers, and complex development & manufacturing activities
- Excellent people manager and cross-functional leader, able to lead diverse and complex teams with demonstrated success
- Ability to travel both domestically and internationally, as needed
PREFERRED QUALIFICATIONS
- Previous experience managing CDMOs for outsourced manufacturing
- Extensive understanding of of cGMP regulations
- Previous experience in small molecule and biologics manufacturing
- Previous experience in formulation development for complex products like lipid nanoparticles
BENEFITS
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
Base Salary Range: $163,500 - $190,000
Actual base salary will be determined by relevant professional experience, applicable skills, and internal equity.
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against Covid-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.
Company
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
- Website
- http://www.mammoth.bio/
- Phone
- (650) 294-8583
- Location
-
South San Francisco
CA
94080
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert